Innovation Pharmaceuticals Inc (IPIX)

[Scottwny]

Very good write up. The only thing I would point out is that in the 200mg group, 35% of the Per Protocol population met the primary endpoint. I feel it is misleading to state ALL people met the endpoint that took 200mg of P, especially since we don't know why there was such a difference between total people assigned to 200mg vs. PP population.

I believe the raw data is:

ITT POPULATION
200mg arm: 7/27 patients achieved endpoint
Placebo arm: 4/30 patients achieved endpoint

PP POPULATION
200mg arm: 7/20 patients achieved endpoint
Placebo arm: 3/18 patients achieved endpoint

With a small sample, I think it's helpful to look at the raw data to help put the percentages in perspective. Had our Placebo rate been closer to that of Otezla's placebo rate (about 4% PASI 75), this data would look a lot better.